Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from SoftOx Solutions AS ( (DE:6FV) ) is now available.
SoftOx Solutions AS has announced a breakthrough in the stability of hypochlorous acid (HOCl), a core component of its inhaled therapy for cystic fibrosis. This advancement is pivotal for the company’s inhaled SIS program and could lead to broader applications, including biological defense and treatment of non-CF bronchiectasis, with a proof-of-concept trial scheduled for Q1 2026.
More about SoftOx Solutions AS
SoftOx Solutions AS is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo, focusing on developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. Their technology is developed in collaboration with leading Nordic research institutes.
Average Trading Volume: 20,626,568
Current Market Cap: NOK188.1M
See more data about 6FV stock on TipRanks’ Stock Analysis page.